Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing-Reference-Cited by-同舟云学术

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing

Published:2011-10-17 Issue:44 Volume:108 Page:18032-18037
ISSN:0027-8424
Container-title:Proceedings of the National Academy of Sciences
language:en
Short-container-title:Proceedings of the National Academy of Sciences

Author:

Walsh T.,Casadei S.,Lee M. K.,Pennil C. C.,Nord A. S.,Thornton A. M.,Roeb W.,Agnew K. J.,Stray S. M.,Wickramanayake A.,Norquist B.,Pennington K. P.,Garcia R. L.,King M.-C.,Swisher E. M.

Publisher

Proceedings of the National Academy of Sciences

Subject

Multidisciplinary

Reference32 articles.

1. Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

2. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer

3. BRCA1andBRCA2mutations account for a large proportion of ovarian carcinoma cases

4. Germline mutations in RAD51D confer susceptibility to ovarian cancer

5. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

Cited by 809 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Use of Lipid-based Nanocarriers to Improve Ovarian Cancer Treatment: An Overview of Recent Developments;Current Pharmaceutical Biotechnology;2024-12

2. Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations;Gynecologic Oncology;2024-11

3. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024;European Journal of Obstetrics & Gynecology and Reproductive Biology;2024-09

4. Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors;Gynecologic Oncology;2024-08

5. Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients;Gynecologic Oncology;2024-08